Safety Group Asks FDA to Block Peptide Compounding

A drug-safety advocacy coalition has asked FDA not to let pharmacies compound seven increasingly popular peptides, arguing the agency's own advisory committee got the question wrong — and was improperly stacked to begin with. The Partnership for Safe Medicines (PSM) filed a citizen petition around October 16, 2026, publicized October 21, taking direct aim at a July 2026 vote by FDA's Pharmacy Compounding Advisory Committee that recommended adding six of the seven peptides to the bulk-compounding list over the objections of FDA's own scientific reviewers.

What is actually being contested

Section 503A of the Federal Food, Drug, and Cosmetic Act lets state-licensed pharmacies and physicians compound individualized prescriptions from bulk drug substances, provided the substance meets certain conditions — among them, appearing on FDA's 503A Bulk Drug Substances List. A substance placed in Category 1 of that list can be compounded without the clinical-trial safety and efficacy data an approved drug would require. For a class of peptides that has seen surging off-label and wellness-market interest — BPC-157 and TB-500 among the best known, marketed informally for tissue repair and recovery — a Category 1 listing would effectively open a legal compounding pathway that does not currently exist for them nationwide. PSM's petition is an attempt to stop that listing before FDA finalizes it.

The July 2026 vote PSM is challenging

FDA's Pharmacy Compounding Advisory Committee met in July 2026 to evaluate these peptides against the statutory and regulatory criteria for bulk-list eligibility — whether a compounded version is necessary because no FDA-approved alternative exists, and whether the substance has an established safety and efficacy profile that supports compounding without full clinical trial review. FDA's own scientific reviewers reportedly recommended against listing any of the seven, citing a lack of adequate human safety and efficacy data. The committee voted 8-6 to recommend six of the seven anyway. PSM's petition argues that outcome should not stand because of who was on the committee: it alleges that newly appointed PCAC members held financial ties to the peptide industry, and that empaneling them without proper disclosure or process violated the Federal Advisory Committee Act's transparency requirements and the Ethics in Government Act's conflict-of-interest rules. These are PSM's own legal characterizations; Regulatory News did not locate an independent legal analysis corroborating the merits of the FACA/ethics claims specifically, though PCAC's membership and potential conflicts of interest have been separately criticized by other groups, including Public Citizen and CSPI, in comments distinct from PSM's petition.

Why RA/QA teams should track this

• Compounding pharmacies and 503A-reliant practices: if FDA finalizes a Category 1 listing for these peptides, compliance exposure shifts from “can we legally compound this” to standard 503A operational requirements — a meaningful change for any pharmacy currently treating these substances as a grey area.
• Drug and device manufacturers with competing or adjacent products: a bulk-list peptide pathway, reached without clinical trial data, is a different competitive and reimbursement landscape than an approved drug — sponsors developing their own peptide therapeutics should track whether this expands or narrows the compounded alternative's footprint.
• Anyone relying on PCAC or similar FDA advisory-committee outcomes: PSM's procedural challenge, if it gains traction, is a reminder that an advisory committee's recommendation is not self-executing and can be contested on process grounds separate from the scientific merits — relevant precedent for how much weight to place on an advisory vote before FDA's final action.

What is not yet settled

FDA has not publicly responded to PSM's petition, and citizen petitions commonly take months or years to resolve. The agency has also not announced a final decision on adding the seven peptides to the 503A Bulk Drug Substances List following the July 2026 PCAC vote. Regulatory News could not locate a confirmed FDA docket number for PSM's petition in the sourcing available and will update this story if one is published. RA/QA teams should treat both the bulk-list question and PSM's procedural challenge as open until FDA rules on either.

Frequently asked questions

What did the Partnership for Safe Medicines ask FDA to do?

Filed a citizen petition asking FDA to refrain from rulemaking, Category 1 listing, or enforcement discretion that would let pharmacies compound seven peptides: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), semax and epitalon.

Why does PSM say the underlying advisory vote should be set aside?

PCAC voted 8-6 in July 2026 to recommend six of the seven peptides for the bulk list, overriding FDA's own reviewers. PSM alleges the committee was improperly constituted, with members holding industry financial ties, violating FACA and ethics rules.

What is the 503A Bulk Drug Substances List, and why does it matter?

A list that lets 503A pharmacies legally compound a substance without the clinical trial data an approved drug requires. A Category 1 listing for these peptides would open a compounding pathway that does not currently exist for them nationwide.

Has FDA ruled on the petition or the peptides' bulk-list status?

No. Neither the petition nor the underlying bulk-list decision has been finalized as of this writing.